Pharmaceutical - Bydureon


Current filters:


Popular Filters

FDA approves Bydureon Pen for type 2 diabetes

FDA approves Bydureon Pen for type 2 diabetes


Anglo-Swedish drug major AstraZeneca says the US Food and Drug Administration has approved the Bydureon…

AlkermesAmylinAstraZenecaBristol-Myers SquibbBydureonDiabetesPharmaceuticalRegulationUSA

Head-to-head trial of diabetes drugs Victoza and Bydureon yields mixed results


A direct, head-to-head comparison of two of the newer treatments available for type 2 diabetes yielded…

AmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

South Korea's type 2 diabetes drug market to grow to over $550 million in 2016


The type 2 diabetes therapeutic market in South Korea will grow 11% annually from $330 million in 2011…

AmylinAsia-PacificBydureonDiabetesJanumetJanuviaMarkets & MarketingMerck & CoNovo NordiskPharmaceuticalVictoza

UK NICE says yes to Lilly’s Bydureon and ALK-Abello’s Pharmalgen


The UK’s health care guidance body the National Institute for Health and Clinical Excellence (NICE),…

ALK AbelloBydureonDiabetesEli LillyEuropePharmaceuticalPharmalgenPricingRegulationRespiratory and Pulmonary

FDA finally approves Bydureon


There was good news on Friday for USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) and Alkermes (Nasdaq:…

AlkermesAmylinBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Mixed NICE recommendations for CML and diabetes drugs


In a batch of final guidances released this morning by the UK’s drug watchdog the Institute for…

Bristol-Myers SquibbBydureonDiabetesEli LillyEuropeGlivecNovartisOncologyPharmaceuticalPricingRegulationSprycelTasigna

UK NICE draft guidance recommends Eli Lilly’s Bydureon for type 2 diabetes


The UK drugs watchdog the National Institute of Health and Clinical Excellence (NICE) today published…

BydureonDiabetesEli LillyEuropePharmaceuticalPricingRegulation

Strong new data on Novo Nordisk’s Victoza and Lilly/Amylin’s Bydureon presented at EADS


A significantly higher proportion of patients reached the target for blood sugar control (HbA1c target…

AlkermesAmylinBydureonDiabetesEli LillyNovo NordiskPharmaceuticalResearchVictoza

US FDA sets PDUFA action dates for Bydureon and peginesatide


US drugmakers Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY) and Alkermes (Nasdaq: ALKS)…

AffymaxAlkermesAmylinBydureonDiabetesEli LillyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Amylin and Eli Lilly submit CRL reply on Bydureon to US FDA


US biotech Amylin Pharmaceuticals (Nasdaq: AMLN), drug major Eli Lilly (NYSE: LLY) and partner Alkermes…

AlkermesAmylinBiotechnologyBydureonDiabetesEli LillyNorth AmericaPharmaceuticalRegulation

Back to top